SCHEMBL20726728

SCHEMBL20726728

c1ccc2cc(-c3ccc(-c4nc(-c5ccc6ccc7cccnc7c6n5)nc(-c5ccc6ccc7cccnc7c6n5)n4)cc3)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.46
CYP19A1 P11511 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 3/20 0.46
TP53 P04637 3/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 2/20 0.46
CCR1 P32246 2/20 0.46
CCR5 P51681 2/20 0.46
CCR8 P51685 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
GMNN O75496 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MMP2 P08253 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MMP9 P14780 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20726726 0.94 SMN1; SMN2 (0.48) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL20726759 0.90 SMN1; SMN2 (0.47) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL20726744 0.90 MAPT (0.50) SMN1; SMN2KDM4ETP53LMNAMAPT
SCHEMBL19486737 0.88 CYP11B1 (0.44) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL20363802 0.88 SMN1; SMN2 (0.52) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL23075072 0.87 CYP1A1 (0.47) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL20726812 0.86 LMNA (0.53) SMN1; SMN2KDM4ETP53LMNAMAPT
SCHEMBL23016127 0.86 NPC1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL24475691 0.86 TOP1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL24454180 0.86 TOP1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190051841-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2019-02-14 US disclosed
EP-3441391-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME Samsung Display Co., Ltd. (KR) 2019-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190051841-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AOC2, CYP1A1, CRY1 CYP17A1 1689/4885CYP19A1 35/4885CYP11B1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.